Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku to Open Representative Office in Beijing
December 2, 2011
- DSP, Yoshitomiyakuhin to Terminate Copromotion Agreement for Antipsychotics Lonasen, Lullan
December 2, 2011
- Confusion Seen Temporarily Over FDA Approval for Lipitor Generic
December 2, 2011
- Generic Drug Makers to Continue Launching Generics of Major Drugs Even with 60% Rule
December 2, 2011
- Teva Receives Tentative Approval for Generic Lipitor in the US
December 2, 2011
- Fuji-Keizai Sees Domestic Biopharamaceutical Market Reaching Nearly ¥1 Trillion in 2015
December 1, 2011
- UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
- Sandoz Files Application for Additional Indication, Dosage, Administration for Anticancer Drug Paclitaxel Based on Data in Public Domain
December 1, 2011
- I'rom HD Sells All I'rom Pharmaceutical Shares to Kyowa Pharmaceutical Industry
December 1, 2011
- DSP Files NDA for Fixed-Dose Combination of ARB Avapro (Irbesartan) / CCB Amlodin (Amlodipine)
December 1, 2011
- Hamari Chemicals Announces New San Diego Research Center
December 1, 2011
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 1, 2011
- Ranbaxy Launches Generic Lipitor; Marketing Tie-up with Teva
December 1, 2011
- Sawai Aims at Sales of ¥10 Billion for Lipitor Generic
November 30, 2011
- Products Manufactured by BVL of the US Recalled in Response to EMA Recommendation
November 30, 2011
- US FDA Accepts NDA for Potential MS Treatment Carfilzomib: Ono
November 30, 2011
- Shionogi to Implement Organizational Change to Boost Domestic Sales Strength
November 29, 2011
- Pfizer Japan Obtains Approval for Additional Indication for Deep Mycosis Drug Diflucan
November 29, 2011
- AZ to Bolster Its Top Position in Breast Cancer Area
November 29, 2011
- Paraplatin Approved for Breast Cancer: BMKK
November 29, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…